Premium
Tumor Redox Heterogeneity‐Responsive Prodrug Nanocapsules for Cancer Chemotherapy
Author(s) -
Wang Jinqiang,
Sun Xuanrong,
Mao Weiwei,
Sun Weilin,
Tang Jianbin,
Sui Meihua,
Shen Youqing,
Gu Zhongwei
Publication year - 2013
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201300929
Subject(s) - nanocapsules , prodrug , materials science , redox , chemotherapy , cancer chemotherapy , cancer therapy , nanotechnology , cancer research , combinatorial chemistry , cancer , pharmacology , medicine , nanoparticle , chemistry , metallurgy
A prodrug forms nanocapsules responsive to tumor GSH/ROS heterogeneity releasing the parent drug SN38 via thiolysis in the presence of GSH (glutathione) or via enhanced hydrolysis due to ROS (reactive oxygen species)‐oxidation of the linker, giving rise to high in vitro cytotoxicity and in vivo anticancer therapeutic activity. The nanocapsules are a suitable size for tumor targeting by means of the EPR effect and have a fixed SN38 loading content of 35 wt%, ideal for translational nanomedicine.